References

Andrews, J. R., N. R. Gandhi, P. Moodley, N. S. Shah, L. Bohlken, A. P. Moll, M. Pillay, G. Friedland, A.W. Sturm, and Tugela Ferry Care and Research Collaboration. 2008. Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. Journal of Infectious Diseases198:1582–1589.

Ben Amor, Y., B. Nemser, A. Singh, A. Sankin, and N. Schluger. 2008. Underreported threat of multidrug-resistant tuberculosis in Africa. Emerging Infectious Diseases 14(9):1345–1352.

Bloom, B. R., and C. J. Murray. 1992. Tuberculosis: Commentary on a reemergent killer. Science257(5073):1055–1064.

CDC (U.S. Centers for Disease Control and Prevention). 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second line drugs—worldwide, 2000–2004. Morbidity and Mortality Weekly Report 55(11):301–305.

CDC. 2009. Plan to combat extensively drug-resistant tuberculosis recommendations of the Federal Tuberculosis Task Force. Morbidity and Mortality Weekly Report 58(RR03):1–43.

CGD (Center for Global Development). 2007. A risky business: Saving money and improving global health through better demand forecasts. The report of the Center for Global Development Global Health Forecasting Working Group. http://www.cgdev.org/content/publications/detail/13784 (accessed January 27, 2009).

Chan, E. D., and M. D. Iseman. 2008. Multidrug-resistant and extensively drug-resistant tuberculosis: A review. Current Opinion in Infectious Diseases 21(6):587–595.

Chou, L., M. Harrington, B. Huff, R. Jefferys, T. Swan, J. Syed, and C. Wingfield. 2008. TAG’s 2008 pipeline report. New York: Treatment Action Group.

Corbett, E. L., C. J. Watt, N. Walker, D. Maher, B. G. Williams, M. C. Raviglione, and C. Dye. 2003. The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Archives of Internal Medicine 163:1009–1021.

Escombe, A. R., D. A. Moore, R. H. Gilman, W. Pan, M. Navincopa, E. Ticona, C. Martínez, L. Caviedes, P. Sheen, A. Gonzalez, C. J. Noakes, J. S. Friedland, and C. A. Evans. 2008. The infectiousness of tuberculosis patients coinfected with HIV. PLoS Medicine 5(9):e188.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 109
References Andrews, J. R., N. R. Gandhi, P. Moodley, N. S. Shah, L. Bohlken, A. P. Moll, M. Pillay, G. Friedland, A. W. Sturm, and Tugela Ferry Care and Research Collaboration. 2008. Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. Journal of Infectious Diseases 198:1582–1589. Ben Amor, Y., B. Nemser, A. Singh, A. Sankin, and N. Schluger. 2008. Underreported threat of multidrug-resistant tuberculosis in Africa. Emerging Infectious Diseases 14(9):1345–1352. Bloom, B. R., and C. J. Murray. 1992. Tuberculosis: Commentary on a reemergent killer. Science 257(5073):1055–1064. CDC (U.S. Centers for Disease Control and Prevention). 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second line drugs—worldwide, 2000–2004. Morbidity and Mortality Weekly Report 55(11):301–305. CDC. 2009. Plan to combat extensively drug-resistant tuberculosis recommendations of the Fed- eral Tuberculosis Task Force. Morbidity and Mortality Weekly Report 58(RR03):1–43. CGD (Center for Global Development). 2007. A risky business: Saing money and impro- ing global health through better demand forecasts. The report of the Center for global Deelopment global Health Forecasting Working group. http://www.cgdev.org/content/ publications/detail/13784 (accessed January 27, 2009). Chan, E. D., and M. D. Iseman. 2008. Multidrug-resistant and extensively drug-resistant tuberculosis: A review. Current Opinion in Infectious Diseases 21(6):587–595. Chou, L., M. Harrington, B. Huff, R. Jefferys, T. Swan, J. Syed, and C. Wingfield. 2008. TAg’s 00 pipeline report. New York: Treatment Action Group. Corbett, E. L., C. J. Watt, N. Walker, D. Maher, B. G. Williams, M. C. Raviglione, and C. Dye. 2003. The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Archies of Internal Medicine 163:1009–1021. Escombe, A. R., D. A. Moore, R. H. Gilman, W. Pan, M. Navincopa, E. Ticona, C. Martínez, L. Caviedes, P. Sheen, A. Gonzalez, C. J. Noakes, J. S. Friedland, and C. A. Evans. 2008. The infectiousness of tuberculosis patients coinfected with HIV. PloS Medicine 5(9):e188. 0

OCR for page 109
0 THREAT OF DRug-RESISTANT TubERCulOSIS Fauci, A. S. 2008. Multidrug-resistant and extensively drug-resistant tuberculosis: The National Institute of Allergy and Infectious Diseases research agenda and recommendations for priority research. Journal of Infectious Diseases 197(11)1493–1498. Frieden, T. R., P. I. Fujiwara, R. M. Washko, and M. A. Hamburg. 1995. Tuberculosis in New York City—turning the tide. New England Journal of Medicine 333(4):229–233. Friedland, G. 2008. HIV/MDR-XDR-TB: Implications. Speaker presentation at the Institute of Medicine Workshop on Addressing the Threat of Drug-Resistant Tuberculosis, November 5, Washington, DC. Gandhi, N. R., A. Moll, A. W. Sturm, R. Pawinski, T. Govender, U. Lalloo, K. Zeller, J. Andrews, and G. Friedland. 2006. Extensively drug-resistant tuberculosis as a cause of 2006. death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. lancet 368:1575–1580. Gandhi, N. R., N. S. Shah, J. R. Andrews, V. Vella, A. P. Moll, M. Scott, P. Baberia, C. Marra, U. Lalloo, and G. Friedland. 2009. High early mortality among HIV-infected patients with multidrug-resistant (MDR) or extensively drug-resistant tuberculosis (XDR TB) in Rural South Africa. Poster presentation at 16th Conference on Retroviruses and Oppor- tunistic Infections, Montreal. Gao, Q. 2008. Transmission of MDR/XDR tuberculosis in Shanghai. Speaker presentation at the Institute of Medicine Workshop on Addressing the Threat of Drug-Resistant Tuber- culosis, November 5, Washington, DC. Gelmanova, I. Y., S. Keshavjee, V. T. Golubchikova, V. I. Berezina, A. K. Strelis, G. V. Yanova, S. Atwood, and M. Murray. 2007. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: Non-adherence, default and the acquisition of multidrug resistance. bulletin of the World Health Organization 85(9):649–732. Ginsberg, A. 2008. TB drug development: Pipeline realities. Speaker presentation at the Insti- tute of Medicine Workshop on Addressing the Threat of Drug-Resistant Tuberculosis, November 5, Washington, DC. Global Health Forecasting Working Group. 2007. A risky business: Saing money and impro- ing global health through better demand forecasts. Washington, DC: CGD. Goldfeld, A. 2008. Drug and health care delivery: A perspective from Cambodia and Ethiopia. Speaker presentation at the Institute of Medicine Workshop on Addressing the Threat of Drug-Resistant Tuberculosis, November 5, Washington, DC. IOM (Institute of Medicine). 2000. Ending neglect: The elimination of tuberculosis in the united States. Washington, DC: National Academy Press. Kent, P. T., and G. P. Kubica. 1985. Public health mycobacteriology: guide for the leel III laboratory. Atlanta, GA: CDC. Pp. 57–63. Keshavjee, S. 2008. Stemming the tide of multidrug-resistant tuberculosis: Major barriers to addressing the growing epidemic. Speaker presentation at the Institute of Medi- Medi- cine Workshop on Addressing the Threat of Drug-Resistant Tuberculosis, November 5, Washington, DC. Keshavjee, S., and K. Seung. 2008. Stemming the tide of multidrug-resistant tuberculosis: Major barriers to addressing the growing epidemic. http://www.iom.edu/Object.File/ Master/60/204/IOM_MDRTB_whitepaper_2009_01_14_FINAL_Edited.pdf (accessed February 17, 2009). Lucas, S. B., A. Hounnou, C. Peacock, A. Beaumel, G. Djomand, J. M. N’Gbichi, K. Yeboue, M. Honde, M. Diomande, C. Giordano, et al. 1993. The mortality and pathology of HIV infection in a West African City. AIDS 7(12):1569–1579. Ministry of Health of the People’s Republic of China. 2000. Nationwide random surey for the epidemiology of tuberculosis in 000: Ministry of Public Health of the People’s Republic of China, 000. Beijing, China: Ministry of Health of the People’s Republic of China.

OCR for page 109
 REFERENCES Moe, J. 2008. Continuing challenge of clinical trial failure: New incentives for neglected disease innovation. Speaker presentation at the Institute of Medicine Workshop on Addressing the Threat of Drug-Resistant Tuberculosis, November 5, Washington, DC. Mohar, A., J. Romo, F. Salido, J. Jessurun, S. Ponce de Leon, E. Reyes, P. Volkow, O. Larraza, M. A. Peredo, C. Cano, G. Gomez, J. Sepúlveda, and N. Mueller. 1992. The spectrum of clinical and pathological manifestations of AIDS in a consecutive series of autopsied patients in Mexico. AIDS 6(5):467–473. Moll, T., N. R. Gandhi, A. W. Sturm, J. Andrews, N. S. Shah, U. G. Lalloo, P. Moodley, and G. Friedland. 2007. Extensively drug-resistant (XDR) TB now more common than MDR-TB in Tugela Ferry, KwaZulu-Natal, South Africa. Poster discussion presented at the 38th Union World Conference on Lung Health, Cape Town. Moodley, P., T. Moll, N. S. Shah, N. R. Gandhi, G. Friedland, U. G. Lalloo, J. Andrews, and A. W. Sturm. 2007. Multidrug- and extensively drug-resistant tuberculosis in KwaZulu- Natal. Poster discussion presented at the 38th Union World Conference on Lung Health, Cape Town. Nardell, E. 2008. How did we get to where we are today? Lack of institutional tuberculosis transmission control. Speaker presentation at the Institute of Medicine Workshop on Addressing the Threat of Drug-Resistant Tuberculosis, November 5, Washington, DC. Nelson, A. M., J. H. Perriens, B. Kapita, L. Okonda, N. Lusamuno, M. R. Kalengayi, P. Angritt, T. C. Quinn, and F. G. Mullick. 1993. A clinical and pathological comparison of the WHO and CDC case definitions for AIDS in Kinshasa, Zaire: Is passive surveillance valid? AIDS 7(9):1241–1245. Nunn, P. 2008. Global incidence of MDR and XDR-TB. Speaker presentation at the Insti- Insti- tute of Medicine Workshop on Addressing the Threat of Drug-Resistant Tuberculosis, November 5, Washington, DC. Pillay, M., and A. W. Sturm. 2007. Evolution of the extensively drug-resistant F15/LAM4/ KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clinical Infectious Diseases 45:409–414. Porter, M. E. 2008. Why America needs an economic strategy: The Harard business School com- petitieness guru offers his prescription for long-term prosperity. http://www.businessweek. com/magazine/content/08_45/b4107038217112.htm (accessed January 28, 2009). Ridderhof, J. 2008. Laboratory capacity: A global analysis. Speaker presentation at the Insti- tute of Medicine Workshop on Addressing the Threat of Drug-Resistant Tuberculosis, November 5, Washington, DC. Ridley, D. B., H. G. Grabowski, and J. L. Moe. 2006. Developing drugs for developing coun- tries. Health Affairs (Millwood) 25(2):313–324. Shah, N. S., A. Wright, G. H. Bai, L. Barrera, F. Boulahbal, N. Martín-Casabona, F. Drobniewski, C. Gilpin, M. Havelková, R. Lepe, R. Lumb, B. Metchock, F. Portaels, M. F. Rodrigues, S. Rüsch-Gerdes, A. Van Deun, V. Vincent, K. Laserson, C. Wells, and J. P. Cegielski. 2007. Worldwide emergence of extensively drug-resistant tuberculosis. Emerging Infectious Diseases 13(3):380–387. Shah, N. S., R. Pratt, L. Armstrong, V. Robison, K. G. Castro, and J. P. Cegielski. 2008. Extensively drug-resistant tuberculosis in the United States, 1993–2007. Journal of the American Medical Association 300(18):2153–2160. Sloutsky, A. 2008. Untitled presentation. Speaker presentation at the Institute of Medi- cine Workshop on Addressing the Threat of Drug-Resistant Tuberculosis, November 5, Washington, DC. TB Alliance and the Global Alliance for TB Drug Development. 2007. Pathway to patients: Charting the dynamics of the global Tb drug market. http://www.bvgh.org/documents/ TB_Alliance_Pathway_to_Patients_FINAL.pdf (accessed January 27, 2009).

OCR for page 109
 THREAT OF DRug-RESISTANT TubERCulOSIS Towse, A., and H. Kettler. 2005. Advance price or purchase commitments to create markets for treatments for diseases of poverty: Lessons from three policies. bulletin of the World Health Organization 83(4):301–307. Weyer, K., J. Ridderhof, and GLI Working Group. 2007. Symposium presentation at the World Congress on Lung Health in Capetown, South Africa, November 7–8. Willingham, F. F., T. L. Schmitz, M. Contreras, S. E. Kalangi, A. M. Vivar, L. Caviedes, E. Schiantarelli, P. M. Neumann, C. Bern, R. H. Gilman, and the Working Group on TB in Peru. 2001. Hospital control and multidrug-resistant pulmonary tuberculosis in female patients, Lima, Peru. Emerging Infectious Diseases 7(1):123–127. WHO (World Health Organization). 1997. Anti-tuberculosis drug resistance in the world. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994–1997. Geneva, Switzerland: WHO. WHO. 2000. Anti-tuberculosis drug resistance in the world, report no., prealence and trends. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveil- lance. Geneva, Switzerland: WHO. WHO. 2004. Anti-tuberculosis drug resistance in the world, third global report. The WHO/ IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. Geneva, Switzerland: WHO. WHO. 2008a. global tuberculosis control 00: Sureillance, planning, financing. Geneva, Switzerland: WHO. WHO. 2008b. Anti-tuberculosis drug resistance in the world, fourth global report by the WHO/IuATlD global project on anti-tuberculosis drug resistance sureillance. Geneva, Switzerland: WHO. WHO. 2008c. Tb/HIV facts. http://www.who.int/tb/challenges/hiv/tbhiv_facts08_en.pdf (accessed February 17, 2009). Willingham, F. F., T. L. Schmitz, M. Contreras, S. E. Kalangi, A. M. Vivar, L. Caviedes, E. Schiantarelli, P. M. Neumann, C. Bern, R. H. Gilman, and the Working Group on TB in Peru. 2001. Hospital control and multidrug-resistant pulmonary tuberculosis in female patients, Lima, Peru. Emerging Infectious Diseases 7(1):123–127. Zhao, M., X. Li, P. Xu, X. Shen, X. Gui, L. Wang, K. DeRiemer, J. Mei, and Q. Gao. 2009. Transmission of MDR and XDR tuberculosis in Shanghai, China. PloS One 4(2):e4370. doi:10.1371/journal.pone.0004370. Zignol, M., M. S. Hosseini, A. Wright, C. Lambregts-van Weezenbeek, P. Nunn, C. J. Watt, B. G. Williams, and C. Dye. 2006. Global incidence of multidrug-resistant tuberculosis. Journal of Infectious Diseases 194(4):479–485. Zintl, P. 2008. Supply and demand for quality-assured second line TB drugs. Speaker presenta- presenta- tion at the Institute of Medicine Workshop on Addressing the Threat of Drug-Resistant Tuberculosis, November 5, Washington, DC.